CYRX

+ Watchlist + Portfolio

CryoPort, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.31
52-Week Range: $7.61 – $16.89
Market Cap: $846.35M
P/E (TTM): —
EPS (TTM): -0.84
Dividend Yield: —

Advanced Metrics

Price/Book: 1.90
PEG Ratio: 62.13
Return on Equity: -6.54%
Return on Assets: -2.39%
Gross Margin: 47.08%
Operating Margin: -20.45%
Profit Margin: -20.05%
Current Ratio: 2.08
Debt/Equity: 0.47
Total Debt: $232.02M
Free Cash Flow: $-14.68M
Revenue Growth: 7.70%
Earnings Growth: —
Enterprise Value: $727.95M

CYRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$237.28M	$168.66M	$156.77M	$176.18M
Cost of Revenue	$133.40M	$93.33M	$87.11M	$93.12M
Gross Profit	$103.87M	$75.33M	$69.66M	$83.05M
Research & Development	$15.72M	$18.04M	$17.71M	$17.04M
Selling, General & Admin	$120.06M	$108.26M	$109.81M	$102.82M
Operating Expenses	$135.78M	$126.30M	$127.52M	$119.86M
Operating Income	-$31.90M	-$50.97M	-$57.86M	-$36.81M
EBITDA	-$6.19M	-$51.15M	-$69.61M	-$2.10M
Pretax Income	-$35.09M	-$84.21M	-$104.35M	-$32.17M
Income Tax	$2.24M	$345.00K	$359.00K	$1.80M
Net Income	-$37.33M	-$99.59M	-$114.76M	$78.30M
Diluted EPS	-0.93	-2.21	-2.49	1.40
Diluted Shares	48.99M	48.74M	49.35M	50.07M

CYRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$36.59M	$46.35M	$34.14M	$250.49M
Receivables	$43.86M	$42.07M	$25.30M	$33.36M
Inventory	$27.68M	$26.21M	$21.48M	$23.19M
Current Assets	$604.18M	$535.11M	$341.57M	$476.17M
Total Assets	$1.04B	$957.74M	$703.49M	$764.99M
Current Liabilities	$40.85M	$45.61M	$64.56M	$219.02M
Long-Term Debt	$407.06M	$379.89M	$185.03M	$1.09M
Total Debt	$435.91M	$416.00M	$242.54M	$230.72M
Total Liabilities	$482.91M	$468.72M	$301.59M	$262.35M
Retained Earnings	-$542.83M	-$642.42M	-$757.17M	-$688.88M
Shareholders' Equity	$555.84M	$489.02M	$401.90M	$502.64M
Working Capital	$563.33M	$489.50M	$277.01M	$257.16M
Net Debt	$370.53M	$333.69M	$165.34M	—

CYRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.85M	-$757.00K	-$16.32M	-$8.58M
Capital Expenditure	-$24.20M	-$44.90M	-$21.27M	-$19.50M
Free Cash Flow	-$26.05M	-$45.66M	-$37.59M	-$28.09M
Depreciation & Amortisation	$22.77M	$27.49M	$30.76M	$27.71M
Stock-Based Compensation	$20.08M	$22.81M	$19.70M	$11.03M
Investing Cash Flow	-$59.68M	$36.05M	$176.81M	$250.32M
Financing Cash Flow	-$39.17M	-$23.80M	-$161.53M	-$21.07M
Share Repurchases	-$37.96M	$0.00	$0.00	-$10.01M
Net Change in Cash	-$100.71M	$11.49M	-$1.04M	$220.67M

CYRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$41.04M	$45.45M	$44.23M	$45.45M	$47.80M
Cost of Revenue	$22.40M	$24.08M	$22.91M	$23.74M	$25.89M
Gross Profit	$18.64M	$21.38M	$21.32M	$21.71M	$21.91M
Research & Development	$3.93M	$4.12M	$4.52M	$4.47M	$3.91M
Selling, General & Admin	$21.90M	$26.91M	$26.73M	$27.28M	$27.62M
Operating Expenses	$25.84M	$31.03M	$31.26M	$31.74M	$31.53M
Operating Income	-$7.19M	-$9.65M	-$9.93M	-$10.03M	-$9.61M
EBITDA	$1.73M	-$3.83M	$410.00K	-$406.00K	-$2.49M
Pretax Income	-$6.50M	-$11.74M	-$6.53M	-$7.39M	-$9.32M
Income Tax	$234.00K	$274.00K	$165.00K	$1.13M	$108.00K
Net Income	-$11.98M	$105.18M	-$6.94M	-$11.64M	-$10.54M
Diluted EPS	-0.28	2.05	-0.18	-0.27	-0.25
Diluted Shares	49.95M	50.26M	50.13M	49.76M	49.90M

CYRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$36.10M	$243.42M	$255.81M	$250.49M	$272.91M
Receivables	$28.37M	$33.41M	$34.91M	$33.36M	$39.00M
Inventory	$23.34M	$23.04M	$23.33M	$23.19M	$21.75M
Current Assets	$411.28M	$489.49M	$484.84M	$476.17M	$470.54M
Total Assets	$699.84M	$773.93M	$774.33M	$764.99M	$763.61M
Current Liabilities	$74.03M	$30.15M	$30.75M	$219.02M	$224.87M
Long-Term Debt	$185.33M	$185.83M	$186.09M	$1.09M	$1.03M
Total Debt	$242.67M	$228.52M	$230.86M	$230.72M	$230.49M
Total Liabilities	$301.03M	$258.54M	$261.06M	$262.35M	$268.62M
Retained Earnings	-$769.16M	-$668.24M	-$675.24M	-$688.88M	-$699.43M
Shareholders' Equity	$398.81M	$515.39M	$513.27M	$502.64M	$494.99M
Working Capital	$337.25M	$459.34M	$454.09M	$257.16M	$245.67M
Net Debt	$163.71M	—	—	—	—

CYRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.34M	-$7.34M	$2.19M	$919.00K	$3.73M
Capital Expenditure	-$4.08M	-$6.20M	-$4.28M	-$4.94M	-$10.28M
Free Cash Flow	-$8.42M	-$13.55M	-$2.09M	-$4.03M	-$6.55M
Depreciation & Amortisation	$7.65M	$7.30M	$6.42M	$6.36M	$6.40M
Stock-Based Compensation	$3.70M	$2.38M	$2.53M	$2.43M	$2.40M
Investing Cash Flow	$5.92M	$230.04M	$14.31M	$56.00K	$18.72M
Financing Cash Flow	-$189.00K	-$15.86M	-$2.87M	-$2.15M	$85.00K
Share Repurchases	—	—	-$3.75M	-$2.01M	—
Net Change in Cash	$1.39M	$206.83M	$13.63M	-$1.18M	$22.54M

Market Snapshot

About

CryoPort, Inc. is a life sciences logistics company providing temperature-controlled supply chain solutions for the biopharmaceutical industry. The company specializes in the safe and compliant transportation of temperature-sensitive materials including cell and gene therapies, vaccines, biologics, and other pharmaceutical products. CryoPort's services include cryogenic shipping systems, cold chain logistics management, storage solutions, and supply chain consulting. The company serves biopharmaceutical companies, contract research organizations, and healthcare providers engaged in advanced therapy development and commercialization.